Free shipping on all orders over $ 500

Ozuriftamab

Cat. No. M25171

All AbMole products are for research use only, cannot be used for human consumption.

Ozuriftamab Structure
Synonym:

BA302

Size Price Availability Quantity
100ug USD 190 In stock
1mg USD 380 In stock
5mg USD 800 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Ozuriftamab is a naked human IgG1 kappa antibody of receptor tyrosine kinase-like orphan receptor 2 ROR2, can be used to synthesis ADC.

Immobilized human ROR2 at 2 ug/mL can bind Ozuriftamab, EC50=0.114 ug/mL.

Chemical Information
CAS Number 2460399-44-2
Storage Store at ≤ -20℃ for 24 months. Avoid repeated freeze-thaw cycles.
Related ROR Products
Dehydrolithocholic acid

Dehydrolithocholic acid is a bile acid metabolite, which inhibits the diferentiation of TH17 cells by directly binding to the key transcription factor RORγt (Kd=1.13 μM).

SR3335

SR3335 (ML-176) is a selective RORα synthetic ligand, directly binds to RORα, but not other RORs, and functions as a selective partial inverse agonist of RORα in cell-based assays.

SR1078

SR1078 is an agonist of retinoic acid receptor-related orphan receptors (ROR) RORα/γ; increases transcription of RORα target genes; thought to increase p53 stability.

SR 1001

SR 1001 is a RORα/γ inverse agonist with Ki values of 172 and 111 nM, respectively.

GSK2981278

GSK2981278 is a highly potent and selective inverse agonist of retinoic acid receptor-related orphan receptor gamma (ROR gamma).

  Catalog
Abmole Inhibitor Catalog




Keywords: Ozuriftamab, BA302 supplier, ROR, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.